Silk Road Medical Executive Compensation (FY23)
SILK · Executive and director compensation, fiscal 2022 to 2023
Chief executive, fiscal 2023 ◇ Chas McKhann | Median of the other named officers $4,866,640 5 officers, excluding the chief executive | Latest say-on-pay support = June 18, 2024 |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on Silk Road Medical
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 5, 2026Latest filing (8-K): June 20, 2024
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
261 figures on this page: 257 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
More on Silk Road Medical
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Erica Rogers → Chas McKhann
Frequently asked questions
Answers drawn from the data on this page.
Who is Silk Road Medical's chief executive and what were they paid?
Chas McKhann was paid $13,423,834 in total compensation as Chief Executive Officer for fiscal 2023.
What was Silk Road Medical's say-on-pay result?
For fiscal 2023, shareholders backed the say-on-pay proposal with 82.4% of votes cast for or against in favor at the meeting held June 18, 2024.
Which companies are in Silk Road Medical's peer group?
The disclosed peer group includes Alphatec Holdings, Inc., AtriCure, Inc., Glaukos Corporation, Inari Medical, Inc. and Outset Medical, Inc.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Erica Rogers Former President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Lucas Buchanan Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Andrew Davis Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kevin Klemz Executive Vice President, Chief Legal Officer and Secretary | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Richard Ruedy Executive Vice President of Regulatory and Clinical Affairs and Quality Assurance | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Chas McKhann Chief Executive Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Erica Rogers Former President and Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Lucas Buchanan Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Andrew Davis Chief Commercial Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Kevin Klemz Executive Vice President, Chief Legal Officer and Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Richard Ruedy Executive Vice President of Regulatory and Clinical Affairs and Quality Assurance | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew S. Davis | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Andrew S. Davis | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Chas S. McKhann | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Erica J. Rogers | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Kevin M. Klemz | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Kevin M. Klemz | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Lucas W. Buchanan | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Lucas W. Buchanan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Lucas W. Buchanan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Richard M. Ruedy | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Richard M. Ruedy | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Chas McKhann | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Andrew Davis | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/02/2032 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/01/2031 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/27/2030 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 08/13/2030 | |
| RSU | ◇ | ◇ | — | — | |
| Lucas Buchanan | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/02/2032 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/02/2032 | |
| Option | ◇ | — | ◇ | 11/06/2030 | |
| Option | ◇ | — | ◇ | 03/01/2031 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/27/2030 | |
| RSU | ◇ | ◇ | — | — | |
| Erica Rogers | Option | ◇ | — | ◇ | 11/02/2026 |
| Option | ◇ | — | ◇ | 11/02/2026 | |
| Option | ◇ | — | ◇ | 11/02/2026 | |
| Option | ◇ | — | ◇ | 11/02/2026 | |
| Kevin Klemz | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 08/15/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Richard Ruedy | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/02/2032 | |
| Option | ◇ | — | ◇ | 03/01/2031 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/27/2030 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Andrew Davis
Chief Commercial Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Chas McKhann
Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2023
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Jack W. Lasersohn Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Donald J. Zurbay | ◇ | ◇ | — | — | — | — | ◇ |
Rick D. Anderson | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kevin J. Ballinger | ◇ | ◇ | ◇ | — | — | — | ◇ |
Elizabeth H. Weatherman | ◇ | ◇ | ◇ | — | — | — | ◇ |
Tanisha V. Carino, Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Tony M. Chou, M.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Chas S. McKhann served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
- Alphatec Holdings, Inc. ATEC
- AtriCure, Inc. ATRC
- Glaukos Corporation GKOS
- Inari Medical, Inc. NARI
- Outset Medical, Inc. OM
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2023 | June 18, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 21, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 9, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 17, 2021 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Chas McKhann (Chief Executive Officer), FY2023 total compensation $13,423,834 (base salary $105,871) [exec_comp, SEC accession 0001397702-24-000024, filed 2024-04-26]What this page does not include
Everything above is a fact Silk Road Medical disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Silk Road Medical sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
261 figures on this page: 257 cited to the filing that reported them, 4 calculated from figures it prints.
257 cited to the filing
4 calculated from the filing
Documents cited
- 0001397702-24-000040Proposal No. 2 - Advisory Vote to Approve Executive Compensation .
- 0001397702-24-000024DIRECTOR COMPENSATION · GRANTS OF PLAN-BASED AWARDS DURING 2023 · Grants of Plan-Based Awards
- 0001397702-23-000046Proposal No. 2 - Advisory Vote to Approve Named Executive Officer Compensation .
- 0001397702-22-000037Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001397702-21-000044I tem 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Silk Road Medical executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/SILK (accessed 2026).
Short form: data: Velarion
The paid brief for Silk Road Medical
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Silk Road Medical and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Silk Road Medical discloses
The companies named in SILK's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}